Five‐year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma

We report the 5‐year follow‐up results from a single‐arm, open‐label, multicenter phase II study (ONO‐4538‐08) conducted in Japan. Twenty‐four patients with treatment‐naïve, recurrent, or unresectable stage III/IV malignant melanoma received 3 mg/kg nivolumab every 2 weeks until progressive disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhara, Hisashi, Kiyohara, Yoshio, Uehara, Jiro, Fujisawa, Yasuhiro, Takenouchi, Tatsuya, Otsuka, Masaki, Uchi, Hiroshi, Fukushima, Satoshi, Minami, Hironobu, Hatsumichi, Masahiro, Yamazaki, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252056/
https://www.ncbi.nlm.nih.gov/pubmed/33715172
http://dx.doi.org/10.1111/1346-8138.15804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252056/
https://www.ncbi.nlm.nih.gov/pubmed/33715172
http://dx.doi.org/10.1111/1346-8138.15804

Ejemplares similares